This white paper demonstrates the unique benefits that a toxicogenomics approach can bring to toxicity assessment in the drug discovery process.
You’ll see how IPA-Tox®, a capability within IPA®, can help provide improved mechanistic understanding to toxicology programs by more fully leveraging data from genomic platforms. IPA-Tox reveals biological mechanisms that are related to toxicity (on a molecular, cellular, and biochemical level) to help you confidently identify toxic compounds quickly and early in the discovery process. This correlates to a significant reduction in the decision making time when deriving insight from gene expression models (rather than relying on expensive animal studies). This white paper explores the advantages and benefits of a toxicogenomics approach. You’ll also:
Find out what a systems toxicology approach really means
See how to derive actionable insights from genomics data
Learn about established systems toxicology best practices
See where toxicogenomics approaches best complement traditional safety assessment methods
See examples of published research where novel insights were revealed using a systems toxicology approach
Learn how toxicogenomics solutions like IPA-Tox can provide powerful mechanistic understanding for better informed decision-making
Best Practices for Assessing Toxicity throughout the Drug Discovery Process: Toxicogenomics
Learn more about IPA on our website, www.ingenuity.com Click here to register for a free, fully functional trial of IPA.